ticlopidine has been researched along with Facial Neoplasms in 1 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Facial Neoplasms: New abnormal growth of tissue in the FACE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barabash-Neila, R | 1 |
| García-Rodríguez, E | 1 |
| Bernabeu-Wittel, J | 1 |
| Bueno-Rodríguez, I | 1 |
| Ramírez-Villar, G | 1 |
| López-Gutierrez, JC | 1 |
1 other study available for ticlopidine and Facial Neoplasms
| Article | Year |
|---|---|
Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: successful treatment with vincristine and ticlopidine.
Topics: Antineoplastic Agents, Phytogenic; Facial Neoplasms; Hemangioendothelioma; Humans; Infant, Newborn; | 2012 |